Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other financing activities (2016 - 2025)

Fortress Biotech has reported Other financing activities over the past 12 years, most recently at -$2000.0 for Q3 2025.

  • Quarterly results put Other financing activities at -$2000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$1000.0 (changed N/A YoY), and the annual figure for FY2025 was -$1000.0, changed 0.0%.
  • Other financing activities for Q3 2025 was -$2000.0 at Fortress Biotech, down from $2000.0 in the prior quarter.
  • Over the last five years, Other financing activities for FBIO hit a ceiling of $281000.0 in Q4 2021 and a floor of -$6000.0 in Q3 2022.
  • Median Other financing activities over the past 4 years was $1500.0 (2021), compared with a mean of $37500.0.
  • Biggest five-year swings in Other financing activities: surged 118.88% in 2021 and later plummeted 700.0% in 2022.
  • Fortress Biotech's Other financing activities stood at $281000.0 in 2021, then tumbled by 37.01% to $177000.0 in 2022, then plummeted by 103.39% to -$6000.0 in 2023, then surged by 66.67% to -$2000.0 in 2025.
  • The last three reported values for Other financing activities were -$2000.0 (Q3 2025), $2000.0 (Q2 2025), and -$1000.0 (Q1 2025) per Business Quant data.